Skip to product information
Encorafenib – LuciEncor
KSh632,000.00
|
What it treats: |
Inhibits mutated BRAF kinase, part of the MAPK/ERK pathway that drives cancer cell proliferation. Combination therapy with MEK inhibitors helps prevent resistance and reduces some side effects from MAPK overactivation. |
|
BRAF V600E or V600K Mutation-Positive Melanoma |
In combination with binimetinib (a MEK inhibitor) for unresectable or metastatic melanoma. |
|
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC) |
In combination with cetuximab for adults who have received prior therapy. |